Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 9 | 2019 | 1239 | 0.620 |
Why?
|
| Biomarkers | 4 | 2024 | 322 | 0.530 |
Why?
|
| HIV Infections | 14 | 2024 | 4946 | 0.520 |
Why?
|
| Viral Load | 7 | 2021 | 808 | 0.490 |
Why?
|
| Nevirapine | 4 | 2012 | 146 | 0.430 |
Why?
|
| Infectious Disease Transmission, Vertical | 6 | 2021 | 467 | 0.360 |
Why?
|
| Cytokines | 4 | 2021 | 107 | 0.320 |
Why?
|
| Tuberculosis | 2 | 2024 | 530 | 0.300 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 6 | 0.290 |
Why?
|
| HIV Antigens | 1 | 2007 | 26 | 0.280 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2007 | 40 | 0.280 |
Why?
|
| Epitopes | 1 | 2007 | 97 | 0.270 |
Why?
|
| Infant, Newborn | 9 | 2021 | 1410 | 0.260 |
Why?
|
| Anti-Retroviral Agents | 2 | 2021 | 542 | 0.230 |
Why?
|
| Anti-HIV Agents | 5 | 2019 | 1275 | 0.220 |
Why?
|
| Killer Cells, Natural | 4 | 2013 | 50 | 0.220 |
Why?
|
| Chemokine CCL3 | 4 | 2012 | 23 | 0.220 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2021 | 507 | 0.210 |
Why?
|
| Adult | 10 | 2024 | 5664 | 0.200 |
Why?
|
| Gene Dosage | 3 | 2012 | 23 | 0.200 |
Why?
|
| Female | 15 | 2021 | 8751 | 0.200 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2021 | 19 | 0.190 |
Why?
|
| Humans | 17 | 2024 | 14077 | 0.190 |
Why?
|
| Viral Proteins | 2 | 2010 | 30 | 0.170 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.160 |
Why?
|
| Pregnancy | 7 | 2021 | 1815 | 0.150 |
Why?
|
| Infant | 6 | 2021 | 2145 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2024 | 1131 | 0.140 |
Why?
|
| Chemokines, CC | 2 | 2007 | 15 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 43 | 0.140 |
Why?
|
| HIV Antibodies | 2 | 2019 | 243 | 0.140 |
Why?
|
| Receptors, KIR | 2 | 2019 | 23 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 145 | 0.130 |
Why?
|
| Haplotypes | 2 | 2012 | 119 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 14 | 0.110 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 4 | 0.110 |
Why?
|
| Lung | 2 | 2024 | 70 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 28 | 0.110 |
Why?
|
| Signal Transduction | 1 | 2013 | 33 | 0.110 |
Why?
|
| Fetal Blood | 3 | 2007 | 27 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2015 | 468 | 0.100 |
Why?
|
| Lymphocyte Activation | 2 | 2013 | 40 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2011 | 50 | 0.090 |
Why?
|
| Chemoprevention | 1 | 2009 | 33 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 59 | 0.080 |
Why?
|
| Child | 3 | 2021 | 2180 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2007 | 79 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2021 | 939 | 0.070 |
Why?
|
| beta 2-Microglobulin | 1 | 2006 | 4 | 0.070 |
Why?
|
| Neopterin | 1 | 2006 | 4 | 0.070 |
Why?
|
| L-Selectin | 1 | 2006 | 7 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 14 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2012 | 168 | 0.060 |
Why?
|
| Young Adult | 3 | 2021 | 2357 | 0.060 |
Why?
|
| Mothers | 1 | 2006 | 190 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2024 | 6 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 1675 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2024 | 50 | 0.060 |
Why?
|
| Male | 4 | 2021 | 6489 | 0.060 |
Why?
|
| Walk Test | 1 | 2023 | 2 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2023 | 2 | 0.050 |
Why?
|
| Adolescent | 3 | 2021 | 2858 | 0.050 |
Why?
|
| South Africa | 4 | 2021 | 7312 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 22 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 52 | 0.050 |
Why?
|
| HIV | 1 | 2024 | 380 | 0.050 |
Why?
|
| Prognosis | 1 | 2021 | 197 | 0.050 |
Why?
|
| Serogroup | 1 | 2021 | 134 | 0.050 |
Why?
|
| Mortality | 1 | 2021 | 101 | 0.050 |
Why?
|
| Africa South of the Sahara | 2 | 2012 | 328 | 0.050 |
Why?
|
| Middle Aged | 2 | 2021 | 3425 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 25 | 0.040 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 20 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2021 | 320 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 190 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2019 | 54 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2019 | 165 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 303 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 430 | 0.040 |
Why?
|
| Chemokine CCL5 | 2 | 2007 | 9 | 0.040 |
Why?
|
| Chemokine CCL4 | 2 | 2007 | 14 | 0.040 |
Why?
|
| Aged | 1 | 2021 | 1650 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 150 | 0.030 |
Why?
|
| Age Factors | 1 | 2015 | 364 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 40 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 106 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2012 | 47 | 0.030 |
Why?
|
| Ligands | 1 | 2011 | 33 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2010 | 22 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 39 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 117 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2009 | 14 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 65 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2008 | 6 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2008 | 13 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 654 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 260 | 0.020 |
Why?
|
| Disease Progression | 1 | 2008 | 154 | 0.020 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 113 | 0.020 |
Why?
|
| Mitogens | 1 | 2006 | 4 | 0.020 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2006 | 4 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 54 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 60 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2006 | 52 | 0.020 |
Why?
|
| Base Sequence | 1 | 2006 | 149 | 0.020 |
Why?
|
| DNA | 1 | 2006 | 73 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 464 | 0.020 |
Why?
|